Pharmacokinetic profile of lanreotide Autogel® in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days
Bronstein, M., Musolino, N., Jallad, R., Cendros, J. M., Ramis, J., Obach, R., Leselbaum, A., Catus, F.
Published in Clinical endocrinology (Oxford) (01.11.2005)
Published in Clinical endocrinology (Oxford) (01.11.2005)
Get full text
Journal Article
Initial results from the international double-blind phase III study of Dysport® in the treatment of adults with upper limb spasticity
Gracies, J.M, Jech, R, Banach, M, Valkovic, P, Brashear, A, Mcallister, P, Walker, H, Catus, F, Vilain, C, Picaut, P
Published in Annals of physical and rehabilitation medicine (01.05.2014)
Published in Annals of physical and rehabilitation medicine (01.05.2014)
Get full text
Journal Article
Evaluation of the Treatment of Thyrotropin-Secreting Pituitary Adenomas with a Slow Release Formulation of the Somatostatin Analog Lanreotide
Kuhn, J. M, Arlot, S, Lefebvre, H, Caron, P, Cortet-Rudelli, C, Archambaud, F, Chanson, P, Tabarin, A, Goth, Mi, Blumberg, J, Catus, F, Ispas, S, Beck-Peccoz, P
Published in The journal of clinical endocrinology and metabolism (01.04.2000)
Published in The journal of clinical endocrinology and metabolism (01.04.2000)
Get full text
Journal Article
Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995)
CARON, P, COGNE, M, GUSTHIOT-JOUDET, B, WAKIM, S, CATUS, F, BAYARD, F
Published in European journal of endocrinology (01.03.1995)
Published in European journal of endocrinology (01.03.1995)
Get full text
Journal Article
Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide
MAREK, J, HANA, V, KRSEK, M, JUSTOVA, V, CATUS, F, THOMAS, F
Published in European journal of endocrinology (01.07.1994)
Published in European journal of endocrinology (01.07.1994)
Get full text
Journal Article
Treatment of carcinoid syndrome : A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance
O'TOOLE, D, DUCREUX, M, BOMMELAER, G, WEMEAU, J.-L, BOUCHE, O, CATUS, F, BLUMBERG, J, RUSZNIEWSKI, P
Published in Cancer (15.02.2000)
Published in Cancer (15.02.2000)
Get full text
Journal Article
Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide
KUHN, J. M, ARLOT, S, CATUS, F, ISPAS, S, BECK-PECCOZ, P, LEFEBVRE, H, CARON, P, CORTET-RUDELLI, C, ARCHAMBAUD, F, CHANSON, P, TABARIN, A, GOTH, M, BLUMBERG, J
Published in The journal of clinical endocrinology and metabolism (01.04.2000)
Published in The journal of clinical endocrinology and metabolism (01.04.2000)
Get full text
Journal Article
Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans
Lamrani, A., Vidon, N., Sogni, P., Nepveux, P., Catus, F., Blumberg, J., Chaussade, S.
Published in British journal of clinical pharmacology (01.01.1997)
Published in British journal of clinical pharmacology (01.01.1997)
Get full text
Journal Article